04:56 PM EDT, 10/14/2024 (MT Newswires) -- Sight Sciences ( SGHT ) said Monday its TearCare treatment improved symptoms of people with dry eye disease and functional visual outcomes in a trial.

A new study called "Impact of TearCare on Reading Speed in Patients with Dry Eye Disease" has been published in the medical journal Clinical Ophthalmology, the company said.

The single-center study assessed the effects of TearCare therapy on clinical, ocular quality of life, and functional visual outcome indicators in individuals with meibomian gland disease associated dry eye disease.

Key results outlined in the study manuscript include that 52% of participants experienced a notable enhancement in their reading pace following treatment with TearCare, the company said.

Also, there were "significant improvements" in all dry eye disease sign metrics including "tear break-up time, meibomian gland secretion score, and corneal fluorescein staining," Sight Sciences ( SGHT ) said.

Shares of the company were down more than 7% in after-hours trading.

Price: 5.73, Change: -0.45, Percent Change: -7.28